QURE - If that explains yesterday's sell off was it really warranted? Being able to advance straight to pivotal trial with most likely improved therapy and minimal change to the timeline previously outlined for AMT-060 seems like a pretty good trade off for the increased risk that comes with the change. I thought they could capture a small part of the market if approved for people with NAb to other vectors but this could open up a potentially much larger part of the market.
News 
Market Data 
Discover 
